论文部分内容阅读
作者报告用针对重组人肿瘤坏死因子(rh TNF-2)的鼠单克隆抗体CB0006在重症感染性休克病人中进行的Ⅰ期安全性和药效动力学结果。全部患者都被疑诊为败血症。收缩压≤90mmHg者,或血压下降≥40mmHg或至少达30分钟者。在Ⅰ项临床和实验室异常中至少有1项异常(少尿,体温下降或升高,缺氧,呼吸性碱中毒、酸中毒,血小板减少和纤维素降解产物增多)。他们对常规的药物治疗至少在4小时内没有反应,估计寿命至少为24小时。本研究得到伦理委员会同
The authors report phase I safety and pharmacodynamic results with a murine monoclonal antibody CB0006 directed against recombinant human tumor necrosis factor (rh TNF-2) in patients with severe septic shock. All patients were suspected of sepsis. Systolic blood pressure ≤ 90mmHg, or blood pressure drop ≥ 40mmHg or at least 30 minutes. There was at least 1 abnormality (oliguria, hypothermia or hypothermia, hypoxia, respiratory alkalosis, acidosis, thrombocytopenia and increased cellulose degradation products) in Ⅰ clinical and laboratory abnormalities. They have no response to routine medication for at least 4 hours and have an estimated life expectancy of at least 24 hours. This research is supported by ethics committees